ADMA
Price
$16.87
Change
-$0.04 (-0.24%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
4.03B
60 days until earnings call
MDGL
Price
$432.94
Change
+$1.72 (+0.40%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
9.65B
54 days until earnings call
Interact to see
Advertisement

ADMA vs MDGL

Header iconADMA vs MDGL Comparison
Open Charts ADMA vs MDGLBanner chart's image
ADMA Biologics
Price$16.87
Change-$0.04 (-0.24%)
Volume$121.05K
Capitalization4.03B
Madrigal Pharmaceuticals
Price$432.94
Change+$1.72 (+0.40%)
Volume$4.68K
Capitalization9.65B
ADMA vs MDGL Comparison Chart in %
Loading...
ADMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADMA vs. MDGL commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADMA is a Hold and MDGL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ADMA: $16.91 vs. MDGL: $431.21)
Brand notoriety: ADMA and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADMA: 146% vs. MDGL: 65%
Market capitalization -- ADMA: $4.03B vs. MDGL: $9.65B
ADMA [@Biotechnology] is valued at $4.03B. MDGL’s [@Biotechnology] market capitalization is $9.65B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADMA’s FA Score shows that 2 FA rating(s) are green whileMDGL’s FA Score has 1 green FA rating(s).

  • ADMA’s FA Score: 2 green, 3 red.
  • MDGL’s FA Score: 1 green, 4 red.
According to our system of comparison, ADMA is a better buy in the long-term than MDGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADMA’s TA Score shows that 3 TA indicator(s) are bullish while MDGL’s TA Score has 6 bullish TA indicator(s).

  • ADMA’s TA Score: 3 bullish, 6 bearish.
  • MDGL’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than ADMA.

Price Growth

ADMA (@Biotechnology) experienced а -2.73% price change this week, while MDGL (@Biotechnology) price change was -1.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.44%. For the same industry, the average monthly price growth was +9.94%, and the average quarterly price growth was +31.78%.

Reported Earning Dates

ADMA is expected to report earnings on Nov 05, 2025.

MDGL is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+2.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($9.65B) has a higher market cap than ADMA($4.03B). MDGL YTD gains are higher at: 39.745 vs. ADMA (-1.429). ADMA has higher annual earnings (EBITDA): 163M vs. MDGL (-266.74M). MDGL has more cash in the bank: 797M vs. ADMA (90.3M). ADMA has less debt than MDGL: ADMA (83.8M) vs MDGL (124M). MDGL has higher revenues than ADMA: MDGL (516M) vs ADMA (474M).
ADMAMDGLADMA / MDGL
Capitalization4.03B9.65B42%
EBITDA163M-266.74M-61%
Gain YTD-1.42939.745-4%
P/E Ratio19.85N/A-
Revenue474M516M92%
Total Cash90.3M797M11%
Total Debt83.8M124M68%
FUNDAMENTALS RATINGS
ADMA vs MDGL: Fundamental Ratings
ADMA
MDGL
OUTLOOK RATING
1..100
5422
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
67
Overvalued
PROFIT vs RISK RATING
1..100
2626
SMR RATING
1..100
1697
PRICE GROWTH RATING
1..100
6437
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (67) in the Pharmaceuticals Other industry is in the same range as ADMA (70) in the Biotechnology industry. This means that MDGL’s stock grew similarly to ADMA’s over the last 12 months.

MDGL's Profit vs Risk Rating (26) in the Pharmaceuticals Other industry is in the same range as ADMA (26) in the Biotechnology industry. This means that MDGL’s stock grew similarly to ADMA’s over the last 12 months.

ADMA's SMR Rating (16) in the Biotechnology industry is significantly better than the same rating for MDGL (97) in the Pharmaceuticals Other industry. This means that ADMA’s stock grew significantly faster than MDGL’s over the last 12 months.

MDGL's Price Growth Rating (37) in the Pharmaceuticals Other industry is in the same range as ADMA (64) in the Biotechnology industry. This means that MDGL’s stock grew similarly to ADMA’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as ADMA (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to ADMA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADMAMDGL
RSI
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 9 days ago
88%
Bullish Trend 8 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
75%
Bearish Trend 2 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
73%
N/A
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
ADMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FPXE31.580.27
+0.87%
First Trust IPOX Europe Equity Opps ETF
GSEW84.100.61
+0.73%
Goldman Sachs Equal Wght US Lg Cp Eq ETF
JPI20.420.09
+0.42%
Nuveen Preferred Securities & Income Opportunities Fund
PSMO29.830.09
+0.30%
Pacer Swan SOS Moderate (October) ETF
LDRI25.68N/A
N/A
iShares iBonds 1-5 Year TIPS Ladder ETF

ADMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADMA has been loosely correlated with IMTX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ADMA jumps, then IMTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADMA
1D Price
Change %
ADMA100%
+0.03%
IMTX - ADMA
42%
Loosely correlated
+4.95%
IRON - ADMA
40%
Loosely correlated
-2.27%
SYRE - ADMA
39%
Loosely correlated
+1.07%
CPRX - ADMA
39%
Loosely correlated
+0.05%
IMNM - ADMA
39%
Loosely correlated
-4.39%
More

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with NAGE. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then NAGE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
-0.93%
NAGE - MDGL
45%
Loosely correlated
-3.62%
RVMD - MDGL
39%
Loosely correlated
-2.06%
AKRO - MDGL
37%
Loosely correlated
-3.49%
IRON - MDGL
36%
Loosely correlated
-2.27%
ADMA - MDGL
35%
Loosely correlated
+0.03%
More